Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs March 3)
Aerie Pharmaceuticals, Inc. (NASDAQ:
AERI)
Bausch Health Companies Inc. (NYSE:
BHC)
ENDRA Life Sciences Inc. (NASDAQ:
NDRA)
iTeos Therapeutics, Inc. (NASDAQ:
ITOS)
Magenta Therapeutics, Inc. (NASDAQ:
MGTA) (reacted to fourth-quarter results)
MiMedx Group, Inc. (NASDAQ:
MDXG)
Renalytix AI plc (NASDAQ:
RNLX)
Down In The Dumps
(Biotech Stocks Hitting 52-week Lows March 3)
AbCellera Biologics Inc. (NASDAQ:
ABCL)
Athenex, Inc. (NASDAQ:
ATNX)
Brainstorm Cell Therapeutics Inc. (NASDAQ:
BCLI)
Epizyme, Inc. (NASDAQ:
EPZM)
Freeline Therapeutics Holdings plc (NASDAQ:
FRLN)
Galecto, Inc. (NASDAQ:
GLTO)
Inhibikase Therapeutics, Inc. (NASDAQ:
IKT)
Intercept Pharmaceuticals, Inc. (NASDAQ:
ICPT)
Karyopharm Therapeutics Inc (NASDAQ:
KPTI)
Lucira Health Inc (NASDAQ:
LHDX)
Protara Therapeutics, Inc. (NASDAQ:
TARA)
Sana Biotechnology, Inc. (NASDAQ:
SANA)
Sensei Biotherapeutics, Inc. (NASDAQ:
SNSE)
Talis Biomedical Corporation (NASDAQ:
TLIS)
Vallon Pharmaceuticals, Inc. (NASDAQ:
VLON)
Virios Therapeutics, LLC (NASDAQ:
VIRI)
Voyager Therapeutics, Inc. (NASDAQ:
VYGR)
Stocks In Focus
Kiniksa's UK Subsidiary Executes Rilonacept Commercialization Agreement With Regeneron
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:
KNSA) said its U.K. subsidiary Kiniksa U.K. has entered into a commercial supply agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN), under which Regeneron has the exclusive right to manufacture and supply rilonacept for Kiniksa U.K.'s requirements.
The agreement follows Kiniksa executing an asset transfer agreement to Kiniksa U.K. in January.
